Hyperbaric Oxygen Therapy for Long COVID: Evaluating the Clinical Evidence

Hyperbaric oxygen therapy (HBOT), a treatment involving the inhalation of pure oxygen within a pressurized chamber, is gaining traction as a potential intervention for long COVID. While the therapy is well-established for conditions like decompression sickness and non-healing wounds, its application for post-viral symptoms—such as severe brain fog and chronic fatigue—remains experimental and is not currently FDA-approved for this use.

Proponents suggest that HBOT may address the complex physiological damage caused by COVID-19, including microvascular clotting, mitochondrial dysfunction, and persistent inflammation. By increasing the amount of oxygen dissolved in the blood, the therapy may help overcome tissue-level oxygen extraction difficulties and stimulate the release of growth factors that support neuronal repair. These mechanisms offer a theoretical basis for why some patients report significant cognitive and physical recovery after completing intensive treatment protocols.

However, the clinical evidence supporting HBOT remains inconsistent. While some studies, such as a phase 2 trial in Israel, have demonstrated lasting improvements in cognitive function and energy levels, other trials have failed to show a significant advantage over placebos. Experts suggest these discrepancies may stem from variations in treatment duration and frequency, as well as the heterogeneous nature of long COVID itself. Because the condition likely arises from diverse underlying causes—ranging from immune dysregulation to viral persistence—a one-size-fits-all approach may not be effective.

Ultimately, while individual success stories are compelling, the medical community emphasizes the need for larger, standardized clinical trials to determine the therapy's true efficacy. Patients and providers are encouraged to approach HBOT with caution, recognizing that until more robust data emerges, it remains an unproven treatment that requires careful clinical oversight.